Is Glaxosmithkline Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Glaxosmithkline Pharmaceuticals Ltd is a good quality company .

Is Glaxosmithkline Pharmaceuticals undervalued or overvalued?

The key valuation ratios of Glaxosmithkline Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Glaxosmithkline Pharmaceuticals share price return in the past 10 years?

Glaxosmithkline Pharmaceuticals Ltd share price has appreciated 4.4% annually (CAGR) over the past ten years.

Is Glaxosmithkline Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Glaxosmithkline Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Glaxosmithkline Pharmaceuticals?

The latest standalone P/E ratio of Glaxosmithkline Pharmaceuticals as of 20-Dec-2024 is 57.86.

What is the P/B ratio of Glaxosmithkline Pharmaceuticals?

The latest standalone P/B ratio of Glaxosmithkline Pharmaceuticals as of 20-Dec-2024 is 23.11.

What is the 52-week high and low of Glaxosmithkline Pharmaceuticals?

The 52-week high of Glaxosmithkline Pharmaceuticals is Rs. 3087.95 and the 52-week low is Rs. 1668.20.

Glaxosmithkline Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: Glaxosmithkline Pharmaceuticals
Brand: Glaxosmithkline Pharmaceuticals

BSE: 500660 | NSE: GLAXO | Pharmaceuticals & Drugs | Mid Cap

Place order

Glaxosmithkline Phar Share Price

₹2,284.50 -40.75 -1.75%
as on 20-Dec'24 16:59

10 Year X-Ray of Glaxosmithkline Phar:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	39.5%	28.8%	24.4%	26.6%	32.5%	15.8%	27.7%	37.7%	38.1%	46.5%	-
Value Creation Index ⓘ	2.5	1.6	1.2	1.4	1.9	0.4	1.5	2.4	2.4	3.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,690	2,838	2,908	2,871	3,128	3,224	2,926	3,278	3,252	3,454	3,560
Sales YoY Gr.	-	5.5%	2.5%	-1.3%	8.9%	3.1%	-9.3%	12.1%	-0.8%	6.2%	-
Adj EPS ⓘ	24.2	22.1	18	20.3	25.2	12.4	25.5	21.4	35.1	38.7	39.9
YoY Gr.	-	-8.6%	-18.8%	13.3%	24.1%	-50.8%	105.6%	-16.3%	64.2%	10.4%	-
BVPS (₹) ⓘ	86.4	128.9	118.5	121.4	126.3	107.5	87.3	157.2	102.9	105.5	98.7
Adj Net Profit ⓘ	410	374	304	344	427	210	432	362	594	656	675
Cash Flow from Ops. ⓘ	270	139	234	473	409	491	578	811	484	582	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	2.8%	2%	5.7%	6.2%
Adj EPS ⓘ	5.4%	8.9%	14.9%	10.4%
BVPSⓘ	2.2%	-3.5%	6.5%	2.5%
Share Price	4.4%	6.5%	9.4%	30.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	26.8	18.7	14.5	17	20.4	10.6	26.2	17.5	27	37.3	39
Op. Profit Mgn % ⓘ	17.1	16.9	14.4	17.9	19.4	20.8	20.5	23.4	25	26.3	28.9
Net Profit Mgn % ⓘ	15.2	13.2	10.5	12	13.7	6.5	14.8	11	18.3	19	19
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	95	358	573	599	600	340	136	131	139	125	135
Cash Conv. Cycle ⓘ	5	19	24	9	0	7	13	-4	-6	-5	58

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 39.00%

Net Profit is growing at healthy rate in last 3 years 14.90%

Sales growth has been subdued in last 3 years 5.69%

Sales growth is not so good in last 4 quarters at 7.76%

Latest Financials - Glaxosmithkline Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	39.5	39.9
TTM Sales (₹ Cr.)	3,527	3,560
BVPS (₹.) ⓘ	98.9	98.7
Reserves (₹ Cr.) ⓘ	2,054	1,503
P/BV ⓘ	23.11	23.14
PE ⓘ	57.86	57.33

From the Market
52 Week Low / High (₹)	1668.20 / 3087.95
All Time Low / High (₹)	20.31 / 3087.95
Market Cap (₹ Cr.)	38,701
Equity (₹ Cr.)	169.4
Face Value (₹)	10
Industry PE ⓘ	44.3

Management X-Ray of Glaxosmithkline Phar:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Glaxosmithkline Phar

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Glaxosmithkline Phar

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	3,363	2,838	2,908	2,871	3,128	3,224	2,926	3,278	3,252	3,454
Operating Expenses ⓘ	2,788	2,360	2,489	2,366	2,527	2,567	2,327	2,516	2,447	2,545
Manufacturing Costs	398	144	136	137	143	141	137	148	129	143
Material Costs	1,328	1,325	1,398	1,241	1,358	1,308	1,257	1,356	1,285	1,335
Employee Cost	493	443	483	523	537	629	616	610	595	624
Other Costs ⓘ	569	447	473	464	489	489	318	402	439	443
Operating Profit ⓘ	575	478	419	506	601	657	598	762	804	909
Operating Profit Margin (%)	17.1%	16.9%	14.4%	17.6%	19.2%	20.4%	20.4%	23.2%	24.7%	26.3%
Other Income ⓘ	259	123	73	55	102	79	111	76	101	123
Interest ⓘ	0	0	0	0	1	6	4	2	2	2
Depreciation ⓘ	25	25	26	38	49	83	79	68	66	70
Exceptional Items ⓘ	-52	2	46	18	29	-341	-173	12	-1	-144
Profit Before Tax ⓘ	756	578	511	540	683	306	454	779	836	816
Tax ⓘ	279	202	174	189	237	213	167	398	229	226
Profit After Tax	476	376	337	351	445	93	287	381	608	590
PAT Margin (%)	14.2%	13.3%	11.6%	12.2%	14.2%	2.9%	9.8%	11.6%	18.7%	17.1%
Adjusted EPS (₹)	28.1	22.2	19.9	20.7	26.3	5.5	21.1	100.0	36.1	34.8
Dividend Payout Ratio (%)	111%	113%	75%	85%	76%	727%	142%	90%	89%	92%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,829	2,183	2,007	2,057	2,140	1,821	1,478	2,663	1,743	1,787
Share Capital ⓘ	85	85	85	85	169	169	169	169	169	169
Reserves ⓘ	1,744	2,099	1,922	1,973	1,970	1,651	1,309	2,494	1,574	1,617
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	3	2	1	1	0	0	0	0	0	0
Long Term Debt	3	2	1	1	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	308	328	279	506	406	357	466	579	428	625
Others Liabilities ⓘ	993	3,953	4,301	5,075	5,258	845	1,067	1,278	1,022	998
Total Liabilities ⓘ	3,133	6,465	6,588	7,639	7,804	3,023	3,012	4,520	3,193	3,410
Fixed Assets
Gross Block	363	228	299	406	559	1,452	601	592	634	681
Accumulated Depreciation	240	24	46	83	129	696	215	262	305	361
Net Fixed Assetsⓘ	123	204	253	323	430	757	386	329	329	320
CWIP ⓘ	115	268	605	923	1,003	120	13	31	20	14
Investmentsⓘ	0	0	0	0	0	0	0	366	518	813
Inventories	376	526	426	500	486	483	547	535	460	525
Trade Receivables	100	127	171	147	120	100	216	205	192	222
Cash Equivalents ⓘ	1,911	1,392	900	1,296	1,171	1,083	1,158	2,485	1,156	1,063
Others Assetsⓘ	508	3,949	4,233	4,449	4,593	480	692	570	517	452
Total Assets ⓘ	3,133	6,465	6,588	7,639	7,804	3,023	3,012	4,520	3,193	3,410

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	338	139	234	473	409	490	578	811	484	582
PBT ⓘ	808	576	465	522	654	647	723	2,476	841	960
Adjustment ⓘ	-174	-96	-46	-12	-31	13	-26	-1,636	-40	-45
Changes in Working Capital ⓘ	-37	-124	-27	165	-4	44	46	120	-46	61
Tax Paid ⓘ	-252	-206	-161	-202	-194	-180	-147	-112	-265	-254
Cash Flow From Investing Activity ⓘ	180	499	301	-104	-153	-57	418	-406	808	9
Capex	-162	-208	-258	-385	-243	-155	-42	1,232	-43	-28
Net Investments	163	565	472	-335	20	92	225	-1,812	956	-144
Others ⓘ	179	142	87	616	70	6	235	175	-106	181
Cash Flow From Financing Activityⓘ	-497	-638	-511	-307	-358	-428	-696	-524	-1,543	-561
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	-1	-1	-1	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	-1	-4	-4	-2	-1	-2
Dividend Paid ⓘ	-424	-529	-424	-254	-296	-339	-677	-507	-1,525	-542
Others ⓘ	-72	-108	-86	-52	-61	-85	-15	-16	-17	-18
Net Cash Flow ⓘ	21	0	24	62	-102	6	300	-119	-251	29

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	24.95	18.75	16.08	17.26	21.22	4.71	17.42	18.39	27.58	33.43
ROCE (%)	39.53	28.81	24.39	26.56	32.54	15.76	27.74	37.72	38.06	46.49
Asset Turnover Ratio	1.12	0.59	0.46	0.42	0.41	0.62	1.04	0.95	0.84	1.05
PAT to CFO Conversion(x)	0.71	0.37	0.69	1.35	0.92	5.27	2.01	2.13	0.8	0.99
Working Capital Days
Receivable Days	10	15	18	19	16	12	18	21	22	22
Inventory Days	38	58	58	56	58	53	60	55	56	52
Payable Days	82	88	79	115	123	106	120	141	143	144

Glaxosmithkline Pharmaceuticals Ltd Stock News

Glaxosmithkline Pharmaceuticals Ltd FAQs

What is the share price of Glaxosmithkline Phar?

Company share prices are keep on changing according to the market conditions. The closing price of Glaxosmithkline Phar on 20-Dec-2024 16:59 is ₹2,284.5.

What is the market cap of Glaxosmithkline Phar?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Glaxosmithkline Phar stood at ₹38,700.8.

What is the P/E ratio of Glaxosmithkline Phar?

The latest P/E ratio of Glaxosmithkline Phar as of 20-Dec-2024 16:59 is 57.86.

What is the P/B ratio of Glaxosmithkline Phar?

The latest P/B ratio of Glaxosmithkline Phar as of 20-Dec-2024 16:59 is 23.11.

What is the 52-week high and low of Glaxosmithkline Phar?

The 52-week high of Glaxosmithkline Phar is ₹3,088 and the 52-week low is ₹1,668.2.

What is the TTM revenue of Glaxosmithkline Phar?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Glaxosmithkline Phar is ₹3,527 ( Cr.) .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

With the combined heritage of Glaxo Wellcome plc and SmithKline Beecham plc, the company has played a pivotal role in the growth of the healthcare industry for almost a century. GSK has been a leader in India since inception, with a history replete with breakthrough innovations. Through the years, it has set benchmarks in conducting business responsibly, including the ways in which it research, develop, sell, and market its products.

The company is headquartered in Mumbai with various regional and sales hubs across the country. The company has made substantial investments in one large manufacturing facility in Nashik, in the state of Maharashtra.

Business area of the company

The company is engaged in research, manufacture and make available a broad range of medicines and vaccines that benefit people. The company’s Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in anti-infectives and dermatology. Its R&D approach focuses on science related to the immune system, use of genetics and advanced technologies. Meanwhile, Its Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. The company is the leaders in India in the private segment.

Products

Medicines
Vaccines
Prescribing Information
Child-resistant packaging

Award and recognition

2017:

Pharma & Medical Devices Summit & Excellence Awards 2017
GSK India wins the Gold Award at the TISS - CLO Summit
GSK India won the 'Gold award' in the Sales Enablement Category at the Tata Institute of Social Sciences (TISS) - CLO Summit in Mumbai.

2018:

GSK ranked among the 50 best companies in India as per People Capital Index (PCI). GSK was conferred this recognition at the HR Leadership Summit 2018.
GSK won the OPPI Salesforce Excellence Award 2018. The award recognises its efforts in launching and scaling an innovative, mobile based platform for sales readiness.
Tbact bags the Silver award for ‘Brand of the Year - Acute category 2018’ for marketing excellence. This award is a testimony to Teamwork and accountability displayed by each member of the cross functional team associated with Tbact.
The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR. The award was received by members of the Women's Leadership Board.
GSK topped the Access to Medicine Index (ATMI) for the sixth time in a row. ATMI is an independent measure of the top 20 pharmaceutical companies’ efforts to improve access to healthcare in developing countries.
GSK's Corporate Communication and Government Affairs team was recognised by Reputation Today as the 30 Top Corporate Communication Teams in India.
The company has been recognised as one of the 100 Best Companies for Women by Working Mother and AVTAR for the second time in a row. This is an important milestone in its inclusion and diversity journey.
GSK has been recognised as the 'Best Workplaces for Women' by Great Places To Work in India. This award celebrates the efforts of the company's Women's Leadership Initiative towards creating an inclusive work environment.

2019:

GSK won the 2019 D&I in India Best Practices Awards in the 'Advancement of Women' category by Community Business.
GSK won the award for the 'Best Sales and Operations Planning Practice in Pharma' 2019.
T-Bact won 'Brand of the Year' award in the acute category for the second consecutive year in 2019 at the 6th AWACS Awards for marketing excellence.

2020:

GSK was recognised as India’s Best Workplaces for Women 2020 by Great Places to Work
GSK was recognised as 100 Best Companies for Women in India 2020 by Working Mother and AVTAR

Milestones

1924: Glaxo comes to India as H J Foster and Co.
1947: Secondary manufacturing of pharmaceuticals begins at Glaxo’s Worli plant.
1956: Primary production of vaccines begins at Worli plant.
1968: Glaxo is registered as Limited company.
1972: Scientists at Beecham Research laboratories discover Amoxycillin and launch Amoxil, which eventually becomes a widely used antibiotic.
1981: Augmentin was launched by Beecham to combat a wide range of bacterial infections in children and adults and the antiviral Zovirax was launched by Wellcome for harpes infections.
1983: Glaxo’s Nashik factory commissioned.
1999: Glaxo India completes 75 years in India it is ranked ‘India’s most respective company’ by business world and again in 2003.
2001: Legal merger of Glaxo India Limited and SmithKline Beecham Pharmaceuticals (India) Limited to form GlaxoSmithKline Pharmaceuticals Limited.
2015: GSK acquired Novartis vaccines business (excluding influenza vaccines).
2016: Launched Priorix- Tetra.
2018: Launched Infanrix Hexa.
2019: Launched Menveo (Quadrivalent Meningococcal Conjugate Vaccine).
2019: The company has launched Spectrum, an employee resource group for raising awareness on LGBT+ among the employees.
2019: Launched a development programme GSK WeLeAP - GSK Women Leadership Action Programme - to develop high potential mid-level women talent.